Compare NTST & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTST | ANIP |
|---|---|---|
| Founded | 2019 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 2020 | 1999 |
| Metric | NTST | ANIP |
|---|---|---|
| Price | $20.69 | $78.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 5 |
| Target Price | $22.02 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 1.2M | 294.9K |
| Earning Date | 04-20-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.29% | N/A |
| EPS Growth | 150.00 | ★ 419.23 |
| EPS | 0.06 | ★ 3.32 |
| Revenue | $195,006,000.00 | ★ $206,547,000.00 |
| Revenue This Year | $19.03 | $21.01 |
| Revenue Next Year | $16.25 | $17.59 |
| P/E Ratio | $340.50 | ★ $23.94 |
| Revenue Growth | ★ 19.79 | 2.47 |
| 52 Week Low | $15.24 | $56.71 |
| 52 Week High | $21.30 | $99.50 |
| Indicator | NTST | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 62.29 | 53.02 |
| Support Level | $17.28 | $78.80 |
| Resistance Level | $21.30 | $83.58 |
| Average True Range (ATR) | 0.43 | 2.41 |
| MACD | 0.05 | -0.04 |
| Stochastic Oscillator | 71.52 | 46.30 |
Netstreit Corp is an internally managed real estate investment trust. The company acquires, owns, and manages single-tenant, retail commercial real estate subject to long-term net leases with high-credit quality tenants across the United States. It focuses on tenants in industries where a physical location is critical to the generation of sales and profits, with a focus on necessity goods and essential services in the retail sector, including home improvement, auto parts, drug stores and pharmacies, general retail, grocers, convenience stores, discount stores, and quick-service restaurants. Majorily operates in U.S. States and Other counties, and derives maximum of revenue from USA.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.